According to data published by who, as early as 2020, colon cancer had risen to the second highest level of cancer in china, with new cases growing fastest, with a mortality rate of 9. 5 per cent。
In particular, 83 per cent of colon cancers are found in the mid-term and late stages, and the horrors of mid-term and late-stage cancer are heard by many. If there's a cure that doesn't operate, but that completely cures mid-term and end-stage rectal cancer, you might think it's a nightmare
However, a 2th issue of the drug clinical trial published in the new england journal of medicine published the pd-1 inhibitor dotali monolithic progress in the field of cancer immunization: 14 patients “total disappearance” of the tumor
What's all this about
14 patients with "total disappearance"
This is a 2-phase clinical study that recruited a total of 30 patients for clinical phase ii and phase iii dyslexia (dmmr) rectal cancer, most of them (78%) with mid-term and end-stage rectal tumours, large tumours and lymphoma transfer。
All patients do not receive chemotherapy treatment, receive 500 mg dotali single-handed daily and follow up after six months. This is followed by follow-up visits every four months for patients who are completely decompressed。
Of the 14 patients who had completed 6 months of treatment, the percentage of total clinical relief was 100 per cent, and during 12 months of mid-level follow-up, no patients had received free chemotherapy, no patients had undergone surgical sterilization, and no patients had experienced a deterioration or relapse。
The clinical decomposition after the dotali monotherapy was complete six months later, and no tumor tissue was observed in the patient's internal mirror work。
Researchers agree that 100 per cent complete relief is a very exciting early signal and a magical cure, but that it needs to be tested in large-scale clinical trials。
Researchers say that the immune cells of the human body contain a protective measure called a checkpoint to prevent them from attacking normal cells. But cancer cells can affect this protection, and thus immunosuppressive cells cannot recognize cancer cells, allowing tumors to hide and grow。
This new treatment is an immunotherapy programme, which focuses on rectal cancer subtypes (dmmrs) where the dna repair system is not functioning. When the repair system does not work, more errors occur in the protein, and the immune system recognizes these errors and kills cancer cells。
According to researchers, the results were surprising, with each patient responding to one drug in clinical trials almost unprecedented。
Researchers have created a term “immunization digestion” for this separate use of immunotherapy targets for specific tumours, which means “immunotherapy as an alternative to surgery, chemotherapy and leaching to eliminate cancer”。
- it's a big benefit in june
Mother-to-child exclusive fungus
The company of infinite love
The limits of magic therapy
Dotali alone demonstrated a strong cancer cure in clinical trials, which is an unprecedented “power of domination”. In terms of safety, 16 patients did not report serious 3 or higher levels of malfeasance, the most common of which were levels 1 or 2, including rashes or inflammation (31 per cent), itching (25 per cent), fatigue and nausea (19 per cent)。
Apart from security concerns, is this magic cure all-powerful
01
Very expensive
According to the british times report, while the dotali monovalence can effectively treat rectal cancer, the cost of treatment is relatively high, at approximately $11,000 per dose (73,000 yuan)。
Patients receive treatment for a period of six months, every three weeks, at a cost of about 600,000 if they complete the full course of treatment. Please note that $600,000 is only the cost of the drug, and the actual cost of treatment must be much higher
For the vast majority of households, it is difficult to afford such expensive treatment. Even “failure” treatment can lead to greater hardship for patients and their families。
02
The patients who benefit are small people
For patients with rectal cancer during the period of progress, the current routine method of clinical treatment is to control conditions such as combination therapy and surgery。
Of these, about 5 to 10 per cent of the patients with rectal cancer are of the dmmr type, i. E., a dna sequence unstable and irretrievable, and the beneficiaries of this magic therapy must be dmmr rectal cancer。
Such patients are not sensitive to chemotherapy, but they produce more new antigens in their bodies, making them more susceptible to immunocellular recognition. In other words, these tumors are the best option for immunisation treatment。
This magic cure is not available to anyone, either economically or in its own right, and therefore best practices for rectal cancer or “early detection and treatment” are the best strategies
Early detection, early diagnosis, early treatment
Focus on symptoms
Decreasing occurs with constipated blood: if there is frequent and unknown blood, it is possible that rectal cancer is knocking on the door. Because rectal cancer causes cell damage to the rectitudinal tissue at the time of its transformation, the patient is exposed to defecation。
The timing of defecation changes: normally, the number of defecations is once a day, and attention is required if the defecation is frequent or frequent. Because cancer cells in the intestinal tract can irritate the intestinal tract, patients at this time have diarrhoea or constipation。
Symptoms of abdominal pain: when cancer cells grow in the body, the size of cancer cells slowly increases. When it reaches a certain level, there is pressure on the surrounding organs, and at this point patients experience an anal swollen pain。
Regular screening
Rectal lenses: rectal lenses and gastrics are similar, allowing for a clear view of the intestinal conditions and pathological examinations of the tissues in which the disease occurs to determine the condition。
Ct test for rectal cancer: ct examination to determine intestinal pathologies. This examination determines whether rectal cancer cells are spreading or can be used to determine the stage of rectal cancer。
Pathological examination of rectal cancer: the pathological examination is an examination required of all rectal cancer patients and is the main basis for diagnosis. Doctors may develop patient-friendly treatment programmes based on patient pathological examinations。
Although dotali's monolithic resistance has shown a strong “ruling power” in the treatment of rectal cancer, only two clinical sessions are currently in need of large-scale testing, with the conclusion that “the bullet will fly a little longer”。
